跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 28,047 条关于
“BRAF V600 Mutated Solid Tumors”
全部
28,047
临床试验
20,510
药物
646
机构
82
资讯
6,809
去年
FORE Biotherapeutics Advances Plixorafenib in BRAF-Driven Tumors, Eyes Potential FDA Submission
去年
FORE Biotherapeutics Secures $38 Million in Series D-2 Financing to Advance Plixorafenib Clinical Trials
4年前
FORE Biotherapeutics Highlights Recent Pipeline Achievements and Strategic Objectives for 2025
5个月前
FORE Biotherapeutics Receives First-Ever Breakthrough Therapy Designation for High-Grade Glioma Targeted Therapy
去年
FORE Biotherapeutics Reports Durable Clinical Benefit with Plixorafenib in BRAF-Altered Thyroid Cancers
2个月前
Nuvectis In-Licenses Two Clinical-Stage Assets from Haisco, Transforming into Late-Stage Biopharma with Oral Factor B and Paradox-Breaker BRAF Inhibitors
2年前
C4 Therapeutics' CFT1946 Shows Promise in BRAF V600 Mutant Solid Tumors
4年前
FDA Approves Novartis' Tafinlar + Mekinist Combo for BRAF V600E-Mutated Solid Tumors
4年前
FDA Grants Accelerated Approval to Dabrafenib and Trametinib Combination for BRAF V600E-Mutated Solid Tumors
8个月前
BEAVER Trial Demonstrates Efficacy of Binimetinib-Encorafenib Combination in Advanced Non-V600E BRAF-Mutated Tumors
第 1 页，共 681 页
上一页
下一页
